Search results for Risankizumab
Risankizumab Biosimilar – Anti-IL23A mAb – Research Grade, ProteoGenix, PX-TA1396
Description of Risankizumab Biosimilar - Anti-IL23A mAb - Research Grade General information on Anti-IL23A[Homo sapiens] (Risankizumab) Monoclonal Antibody Risankizumab is a humanized IgG1 monoclonal antibody (mAb) that targets interleukin 23 (IL-23). It has been used for the treatment of moderate-to-severe plaque psoriasis
Host
Reactivity
Applications
Conjugation
Risankizumab, Abbexa, abx831355
Risankizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL23A, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). On April 23, 2019 it was approved by the FDA (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults who are clinically considered eligible for systemic therapy or phototherapy for psoriasis. Label This drug has been commercialized through collaboration between the German pharmaceutical company, Boehringer Ingelheim, and Abbvie.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Risankizumab Biosimilar - Research Grade, ichor.bio, ICH5210
Detects IL-23_
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.